NiCE Announces Elite Partners of the Year Awards at Interactions 2025, Driving Worldwide Acceleration of CX Automation
BUSINESS WIRE)-- NiCE (Nasdaq: NICE) today announced the winners of the NiCE Elite Partners of the Year award at Interactions 2025, the industry's largest customer experience event, taking place in Las Vegas. The winning partners were recognized for their exceptional contributions to expanding CXone Mpower 's global footprint, enabling more organizations to deliver connected, proactive and automated customer service.
Selected for their commitment to deepening expertise through advanced certifications and delivering differentiated value to customers, the winners exemplify excellence in innovation, execution, and impact. The winners of the NiCE Elite Partners of the Year award are:
Top Global System Integrator – For redefining customer service as a catalyst for proactive growth and delivering seamless, data-driven, and intuitive experiences at scale, the winner is Accenture.
Top Technology Solution Distributor - For expanding the reach of NiCE's solutions by activating a robust network of technology advisors and accelerating momentum across the channel, the winner is Telarus.
Top Carrier Communication Partner – For delivering the connectivity, reliability, and security essential to supporting AI-powered customer experiences at scale, the winner is Verizon.
Top CALA Partner – For showcasing exceptional regional leadership and expertise in advancing CXone Mpower adoption throughout CALA and enabling enterprises to harness the power of next-generation CX automation, the winner is Betta.
Top Canada Partner – For advancing CX innovation in the Canadian market through major infrastructure investments and market leadership in communications and media, the winner is Bell Canada.
Top Public Sector Partner – For enabling government and public service agencies to transform workforce and HR operations through CXone Mpower-driven innovation, the winner is Deloitte GPS.
Top Trusted Advisor – For serving as a strategic partner to clients navigating cloud, cybersecurity, and automation solutions, and helping organizations modernize and elevate the customer experience, the winner is Amplix.
Top DEVone Partner – For redefining real-time collaboration by enabling businesses to instantly add co-browsing and collaborative capabilities to any digital experience and helping over 3,000 organizations streamline customer interactions, the winner is Surfly.
Top Certified Implementation Partner – For delivering seamless CXone Mpower implementations with precision and speed, and helping enterprises across industries drive agility, resilience, and transformation through expert guidance and execution, the winner is Tech Mahindra.
Top Technology Partner – For empowering innovation through globally trusted cloud infrastructure and enabling organizations to deploy AI-powered experiences at speed and scale, the winner is AWS.
Barry Cooper, President, CX Division, NiCE, said, "CXone Mpower is setting a new global standard for AI-driven customer service. It's our partners who help bring this innovation to life, extending our reach, accelerating adoption, and driving measurable outcomes for businesses worldwide. We're proud to recognize this year's winners for their outstanding dedication, expertise, and role in reshaping the future of customer experience.'
About NiCE
NiCE (NASDAQ: NICE) is transforming the world with AI that puts people first. Our purpose-built AI-powered platforms automate engagements into proactive, safe, intelligent actions, empowering individuals and organizations to innovate and act, from interaction to resolution. Trusted by organizations throughout 150+ countries worldwide, NiCE's platforms are widely adopted across industries connecting people, systems, and workflows to work smarter at scale, elevating performance across the organization, delivering proven measurable outcomes.
Trademark Note: NiCE and the NiCE logo are trademarks of NICE Ltd. All other marks are trademarks of their respective owners. For a full list of NICE's marks, please see: www.nice.com/nice-trademarks.
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements, including the statements by Mr. Cooper, are based on the current beliefs, expectations and assumptions of the management of NICE Ltd. (the 'Company'). In some cases, such forward-looking statements can be identified by terms such as 'believe,' 'expect,' 'seek,' 'may,' 'will,' 'intend,' 'should,' 'project,' 'anticipate,' 'plan,' 'estimate,' or similar words. Forward-looking statements are subject to a number of risks and uncertainties that could cause the actual results or performance of the Company to differ materially from those described herein, including but not limited to the impact of changes in general economic and business conditions; competition; successful execution of the Company's growth strategy; success and growth of the Company's cloud Software-as-a-Service business; rapid changes in technology and market requirements; the implementation of AI capabilities in certain products and services, decline in demand for the Company's products; inability to timely develop and introduce new technologies, products and applications; difficulties in making additional acquisitions or difficulties or effectively integrating acquired operations; loss of market share; an inability to maintain certain marketing and distribution arrangements; the Company's dependency on third-party cloud computing platform providers, hosting facilities and service partners; cyber security attacks or other security incidents; privacy concerns; changes in currency exchange rates and interest rates, the effects of additional tax liabilities resulting from our global operations, the effect of unexpected events or geo-political conditions, including those arising from political instability or armed conflict that may disrupt our business and the global economy; our ability to recruit and retain qualified personnel; the effect of newly enacted or modified laws, regulation or standards on the Company and our products and various other factors and uncertainties discussed in our filings with the U.S. Securities and Exchange Commission (the 'SEC'). For a more detailed description of the risk factors and uncertainties affecting the company, refer to the Company's reports filed from time to time with the SEC, including the Company's Annual Report on Form 20-F. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company undertakes no obligation to update or revise them, except as required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Why This Beaten Down Biotech Stock Might Be a Hidden Gem
In the volatile biotech industry, it is easy to overlook small-cap medical device companies, particularly those that are not yet profitable. But every now and then, a company slips under the radar despite having the ideal combination of innovation, market opportunity, and long-term strategic execution. One such company is Alphatec Holdings (ATEC), a medical technology firm specializing in advanced spine surgery solutions. Alphatec uses artificial intelligence (AI) technologies to improve surgical precision, automate signal monitoring, and provide intraoperative analytics. While it is not a pure-play AI company, AI is becoming more integrated into its platform, helping to shape the future of spine surgery. Dear Tesla Stock Fans, Mark Your Calendars for June 22 Nvidia Says Quantum Computing Is Nearing an 'Inflection Point.' Here Are the 3 Best Stocks to Buy Now to Profit. Warren Buffett Loves This Cheap Dividend Stock and So Do Company Insiders Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. With consistent revenue growth, ATEC is gradually gaining traction. Valued at a market capitalization of $1.6 billion, Alphatec stock has risen 21% year to date (YTD), outperforming the S&P 500 Index's ($SPX) gain of 2.2% YTD. Long-term investors who are willing to dig deeper may find this beaten-down growth stock to be a hidden gem. Founded in 1990, Alphatec initially focused on spinal implants and surgical instrumentation. However, it is now reimagining spine surgery as a fully integrated experience, with cutting-edge implants, navigation systems, and surgical software. The company's platform is intended to assist spine surgeons in operating with greater precision, reducing complications, shortening patient recovery times, and collecting intraoperative data for better long-term outcomes. Alphatec has achieved double-digit revenue growth lately, owing to increased surgeon adoption and new product launches. In the first quarter of 2025, total revenue increased 22% year on year to $169 million, with surgical revenue up 24%. Procedure volume is increasing as more surgeons use Alphatec's approaches. The company is quickly becoming a preferred partner for spine surgeons because of its technological capabilities. In Q1, Alphatec experienced an 18% increase in new surgeon adoption. Like most growth companies, Alphatec has yet to turn a profit despite increasing revenues. These losses are largely the result of aggressive reinvestment in growth, research and development (R&D), and surgeon support. During the quarter, the company spent $16.58 million on R&D. Adjusted gross margin reached 70.4% in the quarter. Looking at the firm's consistent revenue growth and margins, profitability may not be far away, especially if the company continues to increase procedure volumes and expand its ecosystem. Adjusted EBITDA stood at $10.5 million in the quarter, up from a $3 million loss in the year-ago quarter. At the end of Q1, Alphatec had $153.2 million in cash and cash equivalents. Management expects adjusted EBITDA of $78 million in 2025, compared to $31 million in the previous year. Analysts covering Alphatec predict that revenue will increase by 20.1% in 2025, in line with management's expectations. Revenue could rise by 18.3% in 2026, with losses gradually declining. The U.S. spine surgery market is large and growing, with a projected value of $20 billion by 2031. Chronic back pain and spinal deformities are on the rise, owing to the aging population and climbing obesity rates. While Alphatec's market share remains small, this allows the company plenty of room to grow. As demand for more precise and less invasive surgeries increases, the few companies like Alphatec with integrated, AI-capable surgical platforms may lead their industry. Of course, growing biotech stocks can be risky. Alphatec faces stiff competition from larger, established players in the medical technology industry, such as Intuitive Surgical (ISRG), Stryker (SYK), and Medtronic (MDT). Furthermore, continued losses may necessitate additional capital raises or risk share dilution. For a company in its early growth stages, however, these risks are manageable, especially given Alphatec's strong traction with both products and customers. Its sole focus on spine surgery also distinguishes the firm as an expert in its field, which is also known as a moat. Still, because Alphatec is a growing biotech company, ATEC is better suited for aggressive investors willing to hold the stock until it reaches its full potential. Last month, H.C. Wainwright analyst Sean Lee reiterated his 'Buy' rating on ATEC stock, citing the company's strong Q1 2025 performance and growth trajectory. Lee emphasized Alphatec's improved profitability, citing consecutive quarters of positive adjusted EBITDA and a decrease in cash burn. The company now expects positive cash flow by year-end, with a projected increase in adjusted EBITDA for 2025. Despite regulatory and financial risks, Lee believes Alphatec is well-positioned for long-term growth. Backed by valuation metrics like EV-to-sales and DCF analysis, Lee set a 12-month price target of $20 per share. Separately, Barclays also maintained a 'Buy' rating on ATEC with a price target of $21. Recently, Lake Street initiated coverage of ATEC stock with a price target of $18 and a 'Buy' rating. According to the analyst, Alphatec is the only major spine company fully committed to improving spinal surgery outcomes, while the rest of the industry appears disorganized or uncertain. Lake Street also predicts that Alphatec's exceptional growth rate will continue. On Wall Street, ATEC is rated a 'Strong Buy' by consensus. Of the 11 analysts covering the stock, nine have rated it a 'Strong Buy' while one analyst recommends a 'Moderate Buy' rating and one rates the stock a 'Hold.' Based on its mean price target of $18.32, Wall Street expects the stock to climb as high as 66% from current levels. Furthermore, the Street-high estimate of $22.50 per share implies potential upside of nearly 105% over the next 12 months. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
34 minutes ago
- Business Upturn
Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering
New Taipei City, Taiwan, June 18, 2025 (GLOBE NEWSWIRE) — Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company'), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, today announced the closing of its initial public offering (the 'Offering') of 2,666,667 ordinary shares (the 'Ordinary Shares') at a public offering price of $7.5 per share for aggregate gross proceeds of approximately $20 million, before deducting underwriting discounts and other offering expenses. The Ordinary Shares commenced trading on Nasdaq Global Market on June 17, 2025, under the ticker symbol 'MENS'. The Offering closed on June 18, 2025. The Company has granted the underwriters an option, exercisable within 45 days from the date of the final prospectus, to purchase up to an additional 400,000 Ordinary Shares at the public offering price, less underwriting discounts, to cover over-allotments, if any. The Company intends to use the net proceeds from the Offering for (i) funding the additional Phase III trials of MCS-2 (API-2) and the new drug application of MCS-2 (40%); (ii) funding earlier phase trials if the Company is unable to demonstrate comparability (25%); (iii) funding the Phase II trial of PCP (10%); (iv) funding the Phase I clinical trial of IC (5%), and (v) general corporate purposes (20%). The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as sole underwriter for the Offering (the 'Underwriter'). Sichenzia Ross Ference Carmel LLP acted as U.S. securities counsel to the Company, and VCL Law LLP acted as U.S. securities counsel to the Underwriter, in connection with the Offering. A registration statement on Form F-1 (File No. 333-277725) relating to the Offering, as amended, was previously filed with the U.S. Securities and Exchange Commission (the 'SEC') and was declared effective by the SEC on June 16, 2025. The Offering was made only by means of a prospectus. Copies of the prospectus related to the Offering may be obtained from Joseph Stone Capital, LLC by standard mail to Joseph Stone Capital, LLC, 585 Stewart Ave., Suite L60-C, Garden City, NY 11530, or via email at [email protected] or by telephone at +1 (888) 302-5548. In addition, a copy of the final prospectus relating to the Offering, dated June 16, 2025, can also be obtained via the SEC's website at Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Jyong Biotech Ltd. Headquartered in Taiwan, Jyong Biotech a science-driven biotechnology company committed to developing and commercializing innovative and differentiated new drugs (plant-derived), mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia. Since its inception in 2002, the Company has built integrated capabilities that encompass all key functionalities of drug development, including early-stage drug discovery and development, clinical trials, regulatory affairs, manufacturing, and commercialization. Leveraging strong research and development capabilities and a proprietary platform, the Company has been developing a series of botanical drug candidates, including its primary botanical drug candidate, MCS-2, another clinical-stage botanical drug candidate, and other preclinical-stage botanical drug candidates. The Company endeavors to develop and supply first-class innovative drugs to meet customers' health needs and seeks to be a valuable business organization that is held in high esteem by the public. For more information, please visit: Forward-Looking Statement This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as 'may, 'will, 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, the Company's statements regarding the intended use of the proceeds from the Offering. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the 'Risk Factors' section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. For more information, please contact: UnderwriterJoseph Stone Capital, LLC (888) 302-5548 [email protected]
Business Upturn
34 minutes ago
- Business Upturn
Willis launches Zest Insurance, a digital revolution for Australian SMEs
MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (NASDAQ: WTW), today launches Zest Insurance, a cutting-edge digital insurance platform tailored specifically for small and medium enterprises (SMEs) in Australia. Zest Insurance represents a bold step forward in the digital transformation of SME insurance. It offers a seamless, fast and intuitive online experience backed by expert broker support. Designed to meet the evolving needs of modern business owners, Zest Insurance empowers SMEs to purchase, manage and renew their insurance policies entirely online. James Baum, Head of Pacific, WTW says: 'The launch of Zest Insurance comes at a pivotal time for the Australian SME market. With 97% of businesses having 20 or fewer employees, the platform is poised to serve a vast and growing segment of the market. Zest Insurance aims to bridge the gap between traditional insurance models and the digital expectations of modern SME owners.' Brent Lehmann, Head of Commercial & Affinity, Pacific at Willis, adds: 'SMEs are the backbone of the Australian economy, yet many still face outdated, complex processes when it comes to insurance. They increasingly demand convenience, speed and tailored insurance solutions. Zest Insurance is our answer to that challenge, bringing together digital convenience and trusted expertise in one powerful platform. It aims to make purchasing business insurance more straightforward for small business owners.' The Australian SME market, valued at over AUD 9 billion in gross written premium, has been slower to adopt digital insurance solutions compared to global counterparts. Zest Insurance aims to close that gap by offering: A fully digital customer journey – from insurance quote to bind, renewal, and policy management, all conducted online. – from insurance quote to bind, renewal, and policy management, all conducted online. Industry-specific insurance solutions – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. – with one dedicated insurer per industry to ensure tailored coverage to protect businesses. User-friendly design – intuitive forms and interfaces built to enhance and simplify the customer experience. – intuitive forms and interfaces built to enhance and simplify the customer experience. Insurance broker support on demand – expert advice available when needed, ensuring confidence and clarity. Zest Insurance will be available initially to businesses in the administration and support services industry, including bookkeepers, payroll services, management and marketing consultants, market research firms and more, with plans to expand industry offerings in future phases. Zest Insurance policies for this first industry will be exclusively underwritten by Chubb, a world leader in insurance. James adds: 'We've built Zest Insurance to be more than just a platform. It's a new way of thinking about SME insurance. It's about simplicity, transparency and putting the customer first. Together, we're setting a new standard for SME insurance, starting in Australia.' For more information, visit: About WTW At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organizations sharpen their strategy, enhance organizational resilience, motivate their workforce and maximize performance. Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success—and provide perspective that moves you. Learn more at Media contact Clara Goh: +65 6958 2542 [email protected] Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
